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AIM The frequency and impact of symptoms experienced by patients with congenital,
childhood, and juvenile-onset myotonic dystrophy (CDM/ChDM/JDM) is not documented.
This report identifies symptomatic areas with the greatest disease burden in an international
population of patients with early-onset myotonic dystrophy type-1 (DM1).
METHOD We distributed surveys to parents of patients with CDM/ChDM/JDM. Patients with
CDM/ChDM/JDM were members of the US National Registry of DM1 Patients and Family
Members, the Canadian Neuromuscular Disease Registry, or the Swedish Health System.
Surveys inquired about 325 symptoms and 20 themes associated with CDM/ChDM/JDM.
Parents identified the importance of each symptom and theme to their affected child. The
prevalence of each symptom and theme were compared across subgroups of patients. The
statistical analysis was performed using Fisher’s exact and Kruskal–Wallis tests.
RESULTS One hundred and fifty parents returned surveys. The most frequently reported
symptomatic themes in children were issues involving communication (81.7%) and problems
with hands or fingers (79.6%). Problems with communication and fatigue were the issues
that were reported to have the greatest impact on childrens’ lives, while 24.1% of children
reported cardiac disorders and 15.8% had problems with anesthesia.
INTERPRETATION A range of symptoms contribute to the burden of disease faced by children
with DM1. Many of these symptoms are under-recognized.

Myotonic dystrophy type-1 (DM1) is a multisystemic,
autosomal dominant disorder caused by an unstable CTG
repeat in the DMPK gene on chromosome 19q13.3.1–3
The CTG repeat length may expand from generation to
generation and be associated with more severe disease
manifestations and an earlier onset of symptoms.4 In
adults, DM1 classically presents with distal weakness, early
onset cataracts, and delayed muscle relaxation (myotonia).4
When manifestations appear at birth, patients are classified
as having congenital myotonic dystrophy (CDM).5,6
Patients who manifest symptoms after 1 year of age and
before 10 years old, are said to have childhood myotonic
dystrophy (ChDM).5 Patients with symptom onset after
age 10 years are considered to have juvenile-onset myotonic dystrophy (JDM). Despite these classifications, myotonic dystrophy likely represents a continuum of disease
severity rather than a series of discrete pathogenic steps.
Patients with CDM may demonstrate their first symptoms during gestation, with reduced fetal movements and
polyhydramnios.7 At birth, infants with CDM may present
698 DOI: 10.1111/dmcn.12948

with hypotonia, respiratory distress, generalized weakness,
failure to thrive, feeding difficulties, or a club-foot deformity.4,6,8 For infants requiring prolonged ventilation, current care indicates a mortality rate as high as 25% during
the first year.9 Children with CDM frequently have intellectual disability and profound dysarthria.10–12 There is
also a higher reported rate of autism spectrum disorder
(ASD)
and
attention-deficit–hyperactivity
disorder
(ADHD) in these children.13
Individuals with ChDM with symptom onset shortly
after 1 year of age experience many of the same symptoms
as children with CDM. Studies have shown that individuals
with ChDM frequently experience intellectual disability
and behavioral disturbances such as ADHD and ASD.12–14
Among the current authors who care for patients with
ChDM (NEJ, CC, A-BE, CRH, and RTM), our anecdotal
clinical experience suggests that children with ChDM with
a later symptom onset often have fewer cognitive symptoms despite having significant hand myotonia (delayed
muscle relaxation after contraction) and fatigue.
© 2015 Mac Keith Press

Some patients with DM1 may develop their first symptom after the age of 10 years, but before adulthood (JDM).
The symptom severity, manifestations, and comorbidities
have not been well described in this cohort.
While, ideally, an individual patient is best suited to
comment on the presence and severity of their symptoms,
young age, developmental delays, or significant cognitive
limitations can all limit the ability of a child with DM1 to
identify and quantify the severity of their symptoms. In
such cases, a surrogate, such as a parent, can provide valuable insight into their child’s condition.15
Previous studies have focused on the discrete symptomatic domains of children with DM1.8,12–14 The current
study seeks to better understand DM1 disease burden and
the relationship between disease manifestations and a
patient’s quality of life as reported by DM1 parents.

MATERIALS AND METHODS
Participants
We identified patients with myotonic dystrophy with an
onset of symptoms before the age of 18 years. In the United States, individuals and parents were recruited from the
National Registry of Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Patients and Family
Members
(www.urmc.rochester.edu/neurology/nationalregistry).16 In Canada, participants and parents were
recruited from the Canadian Neuromuscular Disease Registry and from the site investigator’s (CC) neuromuscular
clinic. In Sweden, participants were identified via rehabilitation center directors. We sent a survey to the parents of
all identified patients with congenital, childhood, and juvenile-onset myotonic dystrophy (CDM/ChDM/JDM). The
mother, father, or primary caregiver was given a 3-month
period to complete and return the survey. The choice of
which parent should complete the survey was left to the
individual families. Paper surveys were distributed, though
respondents could complete the survey by telephone in the
United States and Canada, if desired.
The survey
The survey inquired about 325 potential symptoms of
importance and the 20 symptomatic themes that these
symptoms represent. These symptoms and themes were
previously identified through qualitative interviews with
patients with CDM/ChDM/JDM and their parents.17 The
survey also inquired about symptoms and issues important
to the population with adult-onset DM1.18 Surveys were
constructed and worded for parents or caregivers to comment on the symptoms of their affected child. In cases
where a parent had more than one child with CDM/
ChDM/JDM, they were asked to complete a survey for
each of their children with DM1. Demographics for both
the parent and each child with DM1 were collected. In
addition, parents were asked about their child’s medical
history and developmental milestones. Results regarding
these medical diagnoses (e.g. ADHD, intellectual disability,

•
•
•

What this study adds
Communication issues, fatigue, and problems with hands and fingers are
important in childhood-onset myotonic dystrophy.
The age at onset, CTG repeat length, and age of the child affect the severity of symptoms.
Up to 24% of children with childhood-onset myotonic dystrophy have cardiac
problems at a young age.

difficulty with anesthesia, cardiac problems) were based on
parent report.
To create the Swedish version of the parent proxy surveys,
a native English speaker who was fluent in Swedish translated the survey into Swedish. Two bilingual Swedish physicians reviewed the translation for clarity and grammar. A
native Swedish speaker then back-translated the survey from
Swedish to English.19 The two English versions were
reviewed for compatibility and final corrections were made.
For each symptom, parents identified if their child experienced the symptom and subsequently rated the relative
impact the symptom had on the child’s life using a Likert
scale.
All surveys and methods were approved by local ethics
boards (Institutional Review Board).

Statistical analysis
The prevalence of each symptom and theme were calculated. For children who experienced an individual
symptom, an average life impact score (mean impact) was
calculated (0=‘My child experiences this but it does not
affect his or her life’; 1=‘It affects my child’s life a little’;
2=‘It affects my child’s life moderately’; 3=‘It affects my
child’s life very much’; and 4=‘It affects my child’s life
severely’) and the population impact score (0–4) was calculated as the average life impact score of those endorsing
the symptom, multiplied by the prevalence of the symptom.18
Analyses used parent responses and responses were categorized in several ways. These analyses sought to identify changes associated with age at onset, length of CTG
repeat length, and age of the child at the time the parent
completed the survey. First, responses were analyzed
based on the disease onset of the patient with DM1:
CDM (onset <1y); ChDM (onset between 1–10y); and
juvenile DM1 (onset between 11–17y). Second, responses
were categorized by the CTG repeat length of the child.
Finally, we performed a cross-sectional analysis based on
the age of the child at the time the survey was completed. These age groupings were chosen in consultation
with a pediatric neuropsychologist based on developmental age. Age ranges included: 0 to 4 years, 5 to 7 years, 8
to 11 years, 12 to 17 years, and 18 years and older. To
evaluate for the impact of disease onset (CDM, ChDM,
or JDM), we calculated the life impact score for each
symptomatic theme in our patient groups. Fisher’s exact
tests were employed to compare the prevalence of each
theme across all different subgroups. Kruskal–Wallis tests
were used to compare the life impact scores across differ-
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ent subgroups. A two-tailed p value less than or equal to
0.05 was considered significant.

RESULTS
Demographics
In total, 150 parents responded from the 340 surveys distributed, giving an overall response rate of 44.1% (51%
US registry, 44% Canadian, and 35% Swedish). Mothers
completed the survey 68.7% of the time and fathers
completed the survey 15.0% of the time; both parents
assisted in completing the survey 5.4% of the time and
another caregiver completed the survey 10.9% of the
time. Of the mothers completing the survey, 67.3% had
myotonic dystrophy. Of the fathers completing the survey, 13.6% had myotonic dystrophy. The demographic
data of the children with DM1 is provided in Table I.
Characteristics and medical comorbidities of the children
with DM1, classified by CDM, ChDM, and JDM, are
provided in Table II.

Table SII (online supporting information) provides the
frequency of each theme categorized by the affected child’s
current age, CTG repeat length, and sex. Theme prevalence in DM1 children by country is provided in
Table SIII (online supporting information). Age was associated with an increased prevalence of many of the themes
(Fig. 1a). Problems with the hands or fingers (p=0.002),
emotional issues (p=0.001), fatigue (p=0.009), pain
(p=0.001), inability to do activities (p=0.026), myotonia
(p=0.004), gastrointestinal issues (p=0.014), and social issues
(p<0.001) all increased and were dependent on age.
Themes less prevalent in the 5- to 7-year-old age group
compared to either the 0- to 4-year-old or 8- to 11-yearold age group were problems with shoulders or arms
(p=0.005), changed body image (p<0.001), difficulty thinking (p=0.030), problems choking or swallowing (p=0.008),
and sleep issues (p=0.001).
The frequency of many themes was associated with
CTG repeat length (Fig. 2a). Among these themes,
proximal leg weakness (p=0.02), truncal weakness (p=0.04),
and problems with urinary or bowel control (p=0.003)
were all more frequent in children with high CTG
repeat while myotonia (p=0.001) was less frequent in
patients with longer CTG repeat expansions. A higher
frequency of some themes was associated with a paternal
inheritance of the disease. These themes included: emotional issues (p=0.03), changes in body image (p=0.02),
social issues (p=0.01), and impaired sleep (p=0.008)
(Table SII).

Prevalence of themes and symptoms
The prevalence, average life impact score, and population
impact score of all of the themes and symptoms for all participants with CDM/ChDM/JDM is provided in Table SI
(online supporting information). The most frequent themes
in all children were: communication issues (81.8%); problems with hands or fingers (79.6%); and fatigue (78.6%).
The frequency of problems with hands and fingers, and
fatigue was lower than that reported by patients with
adult-onset DM1 who reported a frequency of 93.5% and
90.8% respectively.18 Among all the individual symptoms,
the most frequently reported issues were hand weakness
(85.1%), difficulty opening jars or bottles (84.3%), and
learning difficulties (83.3%) (Table SI).

Impact of themes and symptoms
Average life impact scores
In children with DM1, the highest life impact scores were,
gastrointestinal issues (2.1), problems with urinary or

Table I: Demographic data

Table II: Comparison of developmental and intellectual characteristics of

Number of children with DM1 studied
Children with DM1, sex (%)
Male
Female
Sex of parent with myotonic dystrophy (%)
Male
Female
Unknown
Mean age of participant with DM1, y (SD)
Mean age of disease onset, y (SD)
Mean CTG repeat length
Race (%)
Asian
Caucasian
Other
Hispanic
Mean gestational age of child with DM1
Complications during pregnancy
Pre-eclampsia or eclampsia
Low birthweight
Polyhydramnios
Preterm labour
Percent unemployed >18y

150

congenital, childhood, and juvenile-onset myotonic dystrophy

61.3
38.7
24.4
70.9
4.7
17.9 (10.2)
3.4 (5.0)
959.0
5.8
89.3
4.9
6.7
38 weeks
% Yes
2.0
18.7
5.3
11.3
86.7

DM1, Myotonic dystrophy type-1.
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Numbera
Mean age, y (SD)
Mean CTG (SD)
Mean age at onset
(SD)
Reported walking
age, mo (SD)
Reported toilet
training age, mo
(SD)
Reported speaking
age, mo (SD)
Intellectual
impairment, %
ADHD, %
Autism spectrum
disorder, %
a

CDM

ChDM

Juvenile
DM

74
13.36 (8.4)
1225.8 (526.4)
0

54
20.4 (9.2)
660.09 (396.9)
5.1 (2.8)

15
31.4 (8.8)
565.7 (129.8)
12.9 (1.3)

24 (13.2)

14 (4.1)

12 (2.4)

57 (42.1)

35 (12.5)

35 (17.4)

31 (25.6)

21 (10.9)

19 (10.2)

45.8

28.3

0

13.7
21.6

28.3
26.9

6.7
0

Seven parents did not provide an age at onset. CDM, congenital
myotonic dystrophy; ChDM, childhood myotonic dystrophy; DM,
myotonic dystrophy; ADHD, attention-deficit–hyperactivity disorder.
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Figure 1: The impact of congenital, childhood, and juvenile-onset myotonic dystrophy by age. (a) Prevalence of themes by age. (b) Mean Likert
response by age. (c) Impact score by age. *Indicates p<0.05.

bowel control (2.1), and decreased performance in social
situations (2.0) had the highest average life impact scores.
These themes are divergent from those themes that have
the greatest effect on adult-onset DM1 patients. In our
previous study, patients with adult-onset DM1 identified
fatigue (2.5), mobility limitations (2.4), and an inability to
do specific activities (2.4) as the themes with the highest
average life impact scores.18 Similar to the frequency of

themes, the impact of some themes was associated with
age (Fig. 1b). These themes included: problems with hands
or fingers (p=0.001), communication issues (p=0.002),
impaired sleep (p<0.001), fatigue (p<0.001), and changed
body image (p=0.046).
The average life impact of one theme, proximal leg
weakness, was associated with CTG repeat length
(p=0.033).
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Figure 2: The association of congenital, childhood, and juvenile-onset myotonic dystrophy with CTG repeat length. (a) Prevalence of themes by CTG
repeat length. (b) Mean Likert response by CTG repeat length. (c) Impact score by CTG repeat length. *Indicates p<0.05.

The average life impact of only one theme, pain,
was associated with which parent had myotonic dystrophy. In instances where the father had the disease, pain
had a higher life impact score for the child (p=0.04)
(Table SII).
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Population impact
The themes with the greatest population impact scores
were: communication issues (1.6), fatigue (1.5), and gastrointestinal issues (1.5). When evaluating individual
symptoms, learning difficulties (2.0), reliance on family

members (1.9), and difficulty with math (1.7) had the
highest population impact scores (Table SI).
During subgroup analysis, the population impact score
of themes in children with DM1 reaching adulthood
(18- to 28-year-old age group) varied depending on
when they first developed symptoms (i.e. if the patient
had CDM, ChDM or JDM) (Fig. S1, online supporting
information). Participants with adult CDM and ChDM
had higher population impact scores than participants
with for all themes with the exception of emotional
issues and problems with urinary and bowel control
(Fig. S1).

Social factors
In total, 87.7% of parents reported that their child needed
some form of special assistance in school. This assistance
included speech therapy (55.3% of children), occupational
therapy (40.7%), physical therapy (35.3%), smaller classroom size (42.7%), or test modification (42%). Augmentive
speech methods were used by 19.2% of the children (sign
language, device, etc.). Children with DM1 currently over
the age of 18 years had significant limitations in their ability to attain employment (Table I).
CDM subgroup analysis
Of the participants with CDM, 77% had hypotonia at
birth, 25.7% had clubfoot, and 42.5% were reported to
have difficulty with breathing at birth. For those requiring
ventilatory assistance (n=43), the mean duration of ventilation was 3 weeks (SD 1.9).
Medical complications
When assessing for anesthesia complications, 15.8% of
patients with early-onset DM1 had difficulty with general
anesthesia, 56.8% were reported to have no difficulty with
anesthesia, and 27.4% had not yet had anesthesia. Diabetes
was diagnosed in 2.7% of the children. Cardiac arrhythmias
were reported in 24.1% of the population with CDM. The
majority of children did not require use of assistive devices
(ankle braces, canes or walkers, wheelchairs, or motorized
wheelchairs) (59.3%). Patients with CMD who did require
assistive devices used: ankle or leg braces (22.7%); canes or
walkers (10.7%); wheelchairs (14.0%); and motorized
wheelchairs (6.0%). A history of scoliosis was reported in
15.9% of children, with 1.4% of the total population with
CDM requiring surgery because of this complication.
DISCUSSION
This study provides parental insight into the disease burden and progression of disease experienced by patients
with early-onset myotonic dystrophy (CDM, ChDM, and
JDM). DM1 parents highlight the wide spectrum of symptomatic disease in early-onset DM1, and identify common
comorbid conditions potentially amendable to screening.
Children with early-onset DM1, particularly those with
CDM, had a high rate of intellectual disability, ADHD,
and ASD compared to the general population. The general

population has an intellectual disability rate of 0.71%.20
Here, parents reported a 45.8% frequency of intellectual
disability in children with CMD and a 28.3% rate in children with ChDM. In addition, the frequency of ASD in
children with CDM and ChDM was 21.6% and 26.9%
respectively, compared to a published frequency of 9% in
the general population.21 For ADHD, the prevalence in
the general population is 5%, compared to 13.1% and
28.1% in the population with CDM and ChDM respectively.22
It is noteworthy that the reported frequency of cardiac
conduction defects was 24% in the children with DM1 in
our study. This finding, and the association between cardiac conduction defects and sudden death in DM123 may
warrant early screening for conduction defects in younger
patients with DM1. Similarly, the high rate of reported
anesthesia complications reinforces previous recommendations regarding careful pre-, peri-, and post-anesthesia care
in all patients with DM1.24
This cross-sectional study provides a preliminary evaluation of symptom progression during pediatric-onset DM1.
There are clusters of symptoms that have the greatest
impact on patients before the age of 5 years. Some of these
symptoms reportedly improved during the next age cohort
(5–7y) before again progressing. We suspect that this
reported course of disease progression is caused by many
factors. These factors likely include standard milestone
acquisition by children, adaptive strategies adopted by
DM1 children and parents, possible parent report bias, and
perhaps pathological disease progression associated with
DM1. Additional longitudinal studies are required for clarification.
Many of the symptoms and themes affecting the burden
of disease in childhood-onset myotonic dystrophy are different than those reported in adult-onset myotonic dystrophy.18 This is likely related to parent symptom perception
and the relatively more severe phenotype associated with
early-onset myotonic dystrophy. The differences between
the clinical manifestations and disease burden experienced
by adult-onset DM1 and childhood-onset DM1 underscores the need to approach patients with childhood-onset
myotonic dystrophy differently and with a focus on the
issues that are of greatest importance to the given population.
Specifically, our survey results highlight that communication problems are important in children with DM1.
Treating clinicians who recognize this issue in patients
with DM1 may consider an early referral for speech therapy. Moreover, the reports of cardiac arrhythmias in our
young patients with DM1 suggest that early cardiac monitoring should be considered. Finally, the significant cognitive, behavioral, and social issues identified reinforce the
role of a multidisciplinary approach in caring for these
children.
When analyzing the disease burden of patients with
early-onset DM1 who reach adulthood, participants who
had CDM had higher population impact scores for most
Impact of Childhood Myotonic Dystrophy Nicholas E Johnson et al.
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themes compared to those who had ChDM and JDM.
This observation supports the possible association between
a later disease onset and a reduced disease severity later in
life.
There are limitations to this study. All items were parent
reported (e.g. the presence or absence of cardiac conduction defects) and not confirmed by a review of medical
records. This is specifically of concern in relation to the
report of medical comorbidities, including the use of a tracheostomy, pacemaker, and the occurrence of anesthesia
complications. Additional research should further investigate the prevalence of these issues as well as the use of a
gastrostomy tube and non-invasive ventilation in the population with DM1. Second, though the response rate was
adequate,25 it is likely that the respondents do not perfectly
represent the world’s population of early-onset DM1 parents. While three countries were represented (and provided
similar parent responses), it is unknown how participants
from other countries would have responded to similar survey questions. Third, our data directly represents the opinions of myotonic dystrophy patient caregivers. While it is
probable that caregivers can provide a reasonable overview
of the disease burden faced by their children, it is possible
that certain components of disease burden are known only
to individual patients and would be misrepresented by our
methods. Additionally, this data is partially provided by
parents with DM1, and their disease manifestations may
bias their report. Additional studies will need to evaluate
the correlation between children with myotonic dystrophy
and caregiver reports of symptoms.

This large cross-sectional, multi-national study helps to
better understand the disease progression and disease burden experienced by patients with early-onset myotonic dystrophy. Future studies will need to evaluate which factors
and treatments can best reduce the disease burden faced by
this population.
A CK N O W L E D G E M E N T S
This research is supported by the Myotonic Dystrophy Foundation. The funding source did not participate in study design, data
analysis, or manuscript decisions. The authors have stated that
they had no interests that might be perceived as posing a conflict
or bias.

SUPPORTING INFORMATION
The following additional material may be found online:
Figure SI: The impact of congenital, childhood, and juvenileonset myotonic dystrophy in adulthood. (a) The impact score for
physical health themes in participants aged 18 to 28 years, as separated by symptom onset. (b) The impact score for physical
health themes in participants aged 18 to 28 years, as separated by
symptom onset.
Table SI: Parent-reported responses to individual and theme
items, including the prevalence, mean impact, and population
impact score.
Table SII: Prevalence and impact of themes by age, (CTG)
repeat length, and inheritance pattern.
Table SIII: Theme responses separated by country of origin.
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